Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06860243 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 16
- Enrollment target
NCT06860243 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 16 participants.
The verdict
NCT06860243, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 16 participants
- Enrollment target
Study Summary
Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when it is given to healthy participants and participants with moderate hepatic (liver) impairment.
Interventions
- DRUG Prednisone
- DRUG Opevesostat
- DRUG Fludrocortisone acetate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 16 participants |
| Start Date | 2025-05-13 |
| Est. Completion | 2026-02-19 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06860243
The ClinicalTrials.gov registry entry for NCT06860243 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 16 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Prednisone is the first listed.
NCT06860243 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06860243 about?
NCT06860243 is a clinical study titled "A Study to Evaluate Opevesostat (MK-5684) in Male Participants With Moderate Hepatic Impairment (MK-5684-009)". Researchers have designed a study medicine called opevesostat as a new way to treat prostate cancer. The purpose of this study is to learn what happens to opevesostat in a person's body over time (a pharmacokinetic \[PK\] study). Researchers will compare what happens to opevesostat in the body when...
What is the current status of trial NCT06860243?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 16 participants. The study started on 2025-05-13. Estimated completion is 2026-02-19.
What interventions are being tested in trial NCT06860243?
The interventions under investigation include: Prednisone (DRUG), Opevesostat (DRUG), Fludrocortisone acetate (DRUG).
Who is sponsoring clinical trial NCT06860243?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.